| Press releases

Formycon and Aristo Pharma are Founding a Joint Venture for the Development of FYB202

Formycon and Aristo Pharma GmbH, a company of the Struengmann-Group, have formed a joint company for the continued development of FYB202, Formycon’s biosimilar candidate for Stelara® (ustekinumab).

Calendar

Prior Capital Market Conference

March 13, 2018; Dreieich-Götzenhain/Germany

Financial reports
gb_teaser-16-illo

Annual Report 2016

Published on:
May 3, 2017

  • Teaser_mitglied-bio-deutschland-en
  • Forschungssiegel_Teaser_Webseite-en
  • Teaser_mitglied-biosimilar-medicines-en
  • teaser-powerlist
  • teaser-wachstumschampion-en
  • pipeline-en-teaser
  • slider04
  • slider06

Formycon is a leading independent pure play developer of biosimilars and has become a recognized innovator in this field. The company has extensive experience in the development of complex biological molecules. Formycon’s specialist expertise allows the company to develop high-quality biosimilars that meet the strict regulatory requirements of highly regulated markets such as Europe and the United States. Formycon currently has four biosimilars under development, with further product candidates already identified. Two biosimilar candidates have already been licensed out.